Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2023)
14 slides from Imugene's shareholder meeting presentation, Nov 30, 2023
Slide 1: Developing Transformative Cancer Medicines - Annual General Meeting 2023
For personal use only ASX: IMU DEVELOPING TRANSFORMATIVE CANCER MEDICINES Annual General Meeting 2023 CEO Presentation Release authorised by the Managing Director and Chief Executive Officer Imugene Limited 1
Slide 2: Disclaimer
DISCLAIMER 1. The information in this presentation does not constitute personal 4. Neither the Company nor any of its directors, officers, employees, investment advice. The presentation is not intended to be advisers, associated persons or subsidiaries are liable for any direct, For personal use onl
Slide 3: International Leadership Team with Extensive Commercialisation Expertise
INTERNATIONAL LEADERSHIP TEAM WITH EXTENSIVE COMMERCIALISATION EXPERTISE IN THE SECTOR For personal use only Imugene has a team with vast oncology drug development experience Leslie Chong Paul Hopper Dr Jakob Dupont Dr Lesley Russell Dr Jens Eckstein Kim Drapkin SYDNEY, AU SYDNEY, AU CALIFORNIA, USA
Slide 4: Imugene Clinical Executive Team
IMUGENE CLINICAL EXECUTIVE TEAM Over 150 years of combined experience in Clinical Development 13 FDA Approved Drugs to market For personal use only Leslie Chong Dr. Paul Woodard, MD Dr Bradley Glover Ursula McCurry Dr. John Byon, MD, PhD Dr Monil Shah Chief Executive Chief Medical Officer Chief Oper
Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS MARKET CAPITALISATION A$752M CASH AS OF A$163M 29 November 2023 US$496M 30 September 2023 US$104M For personal use only IN-HOUSE GMP 3 PRIORITY DISEASE AREAS PLATFORM CELL THERAPY Blood cancers Breast (TNBC) TECHNOLOGIES MANUFACTURING Lung (NSCLC) FACILITIES Gastric Gastroesoph
Slide 6: Key Catalysts for the Next Months
KEY CATALYSTS FOR THE NEXT 12 MONTHS Q4 2024 For personal use only • AZER-CEL: Regulatory Q3 2024 meeting with FDA • AZER-CEL: Phase 1b • ONCARLYTICS: IT & IV Q2 2024 enrollment completed Combo Expansion • AZER-CEL: Phase 1b • ONCARLYTICS: IV • AZER-CEL: DLBCL Phase 2 Q1 2024 Enrollment Status Combi
Slide 7: Commercialisation Strategy
COMMERCIALISATION STRATEGY Clinical Success Drives Value Realisation Opportunities For personal use only • Model for biotech commercialisation strategy is to out- COMPANY ACQUISITION license the technology to Big Pharma • Out-licensing is highly dependent upon demonstrating PARTNER WITH BIG PHARMA s
Slide 8: Cell Therapy and Oncolytic Virus Platforms Deliver Innovative and Potent Therapies
CELL THERAPY AND ONCOLYTIC VIRUS PLATFORMS DELIVER INNOVATIVE AND POTENT THERAPIES TO PATIENTS For personal use only Allogeneic OnCARlytics CF33 CAR T CF33-CD19 Oncolytic Virus B Cell Immunotherapy Cell Therapy OV Therapy (OV) Therapy azer-cel onCARlytics VAXINIA HER-Vaxx & PD1-Vaxx 8
Slide 9: Imugene Is an Industry Leader in Allogeneic Cell Therapy
IMUGENE IS AN INDUSTRY LEADER IN ALLOGENEIC CELL THERAPY For personal use only • Imugene acquired azercabtagene zapreleucel (azer-cel) in August 2023 Mechanism of Action • Phase 1 trial was completed in 84 blood cancer patients with encouraging CD19 is a common molecule found on blood cancers, so sa
Slide 10: Phase 2 Potential Registration Trial
PHASE 2 POTENTIAL REGISTRATION TRIAL For personal use only Potential registrational study (subject to FDA approval) to start upon completion of the Phase 1b study H2 2024 Population: Diffuse large B cell lymphoma (DLBCL) patients who have relapsed after auto CAR T therapy Positive initial FDA guidan
Slide 11: CF33 MAST Study
PHASE 1 CF33 MAST STUDY Making a Meaningful Impact for Patients • The Phase 1 study treats advanced cancer patients intravenously (IV) or For personal use only intratumourally (IT) with CF33-hNIS (VAXINIA) alone, or in combination with pembrolizumab in multiple solid cancers • 34 heavily pre-treated
Slide 12: First Patient Treated with onCARlytics in Phase 1 OASIS Study
FIRST PATIENT TREATED WITH ONCARLYTICS IN PHASE 1 OASIS STUDY OF METASTATIC ADVANCED SOLID TUMOURS For personal use only • The Phase 1 study is designed to treat with onCARlytics (CF33- Combination treatment for CD19) alone, or in combination with Blincyto® (bispecific solid tumours antibody targeti
Slide 13: onCARlytics + azer-cel Eradicates Multiple Tumour Types in Early Preclinical Studies
ONCARLYTICS + AZER-CEL ERADICATES MULTIPLE TUMOUR TYPES IN EARLY PRECLINICAL STUDIES For personal use only Combination treatment for solid tumours • Azer-cel in combination with onCARlytics demonstrated sustained, robust activity against multiple tumour types onCARlytics virus expressing CD19 CAR-T
Slide 14: For personal use only
ASX:IMU For personal use only shareholderenquiries@imugene.com www.imugene.com 14